H.R. 3093 · 118th Congress (2023–2025)
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
This bill requires companies that receive federal funding for research (or a license of the rights to a patent or regulatory test data) for a biomedical product or service to agree to set reasonable prices for the resulting biomedical product or service.
The Department of Health and Human Services (HHS) must determine a reasonable price based on a formula that ensures the U.S. price for the product or service is not more than the median price for the product or service in Canada and six other reference countries with, based on specified criteria, large economies and high incomes.
Companies entering these agreements also must report to HHS certain financial information related to the biomedical product or service involved.
Show official title
To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 3093’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Val T. Hoyle (D-OR-4)
- Cosponsors
18 cosponsors
14 original · 4 later
18 D
- Rep. Steve Cohen (D-TN-9)· Original · May 5, 2023
- Rep. Rosa L. DeLauro (D-CT-3)· Original · May 5, 2023
- Rep. Lloyd Doggett (D-TX-37)· Original · May 5, 2023
- Rep. Raúl M. Grijalva (D-AZ-7)· Original · May 5, 2023
- Rep. Jesús G. "Chuy" García (D-IL-4)· Original · May 5, 2023
- Rep. Pramila Jayapal (D-WA-7)· Original · May 5, 2023
- Rep. Marcy Kaptur (D-OH-9)· Original · May 5, 2023
- Rep. Ro Khanna (D-CA-17)· Original · May 5, 2023
- Del. Eleanor Holmes Norton (D-DC)· Original · May 5, 2023
- Rep. Chellie Pingree (D-ME-1)· Original · May 5, 2023
- Rep. Mark Pocan (D-WI-2)· Original · May 5, 2023
- Rep. Janice D. Schakowsky (D-IL-9)· Original · May 5, 2023
- Rep. Melanie A. Stansbury (D-NM-1)· Original · May 5, 2023
- Rep. Jill N. Tokuda (D-HI-2)· Original · May 5, 2023
- Rep. Greg Casar (D-TX-35)· Later · May 26, 2023
- Rep. Mark Takano (D-CA-39)· Later · Jun 7, 2023
- Rep. Seth Magaziner (D-RI-2)· Later · Jun 13, 2023
- Rep. Rashida Tlaib (D-MI-12)· Later · Aug 4, 2023
- Policy area
- Health
- Subjects
- Government information and archives
- Health care costs and insurance
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · May 5, 2023 – May 12, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
Display title, Short title · Introduced in House
To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.
Official title · Introduced in House